Results of the EORTC 22961 trial

The EORTC Radiation Oncology and Genito-Urinary Tract Cancer Groups reported results of the EORTC 22961 trial on long term or short term androgen suppression combined with irradiation in locally advanced prostate cancer in a paper by Bolla et al. in the 11 June 2009 issue of the New England Journal of Medicine. It is known that combined use of external beam radiotherapy and androgen suppression therapy lasting three years or longer improves overall survival in patients with locally advanced prostate cancer. Still, such long-term androgen suppression therapy can lead to a reduced quality of life for these patients coupled with increased risks of fractures, metabolic syndrome, and possibly myocardial infarction. The question then is if these risks might be lowered and the survival benefit maintained by using a shorter term androgen suppression therapy of only six months duration. In this EORTC study it was found that radiotherapy in combination with short-term (six months) androgen suppression therapy does not maintain the survival benefit achieved with long-term (three years) androgen suppression therapy.

M. Bolla, T. De Reijke, G. Van Tienhoven, A. Van den Bergh, J. Oddens, P. Poortmans, E. Gez, P. Kil, A. Akdas, G. Soete, O. Kariakine, E. van der Steen-Banasik, E. Musat, M. Piérart, M. Mauer, L. Collette, for the EORTC Radiation Oncology Group and Genitor-Urinary Tract Cancer Group. Long term or short term androgen suppression combined with irradiation in locally advanced prostate cancer. N Engl J Med, 360 (24): 2009.

John Bean

Back to news list

Related News

  • EORTC-1333-GUCG/PEACE III trial endpoint reached

  • Meet the new EORTC Board

  • EORTC-1333-GUCG/PEACE III Trial Statement

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration